 LA JOLLA, Calif., April 15, 2021 PRNewswire -- Regulus Therapeutics Inc. Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today announced that it completed dosing in the first cohort of nine patients with ADPKD in its Phase 1b clinical trial of RGLS4326. 